Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
MIRA Pharmaceuticals, Inc. ( (MIRA) ) has shared an announcement.
On July 2, 2025, MIRA Pharmaceuticals announced promising preclinical results for Mira-55, a non-psychoactive marijuana analog, which showed morphine-comparable pain relief in animal models without opioid risks. The drug’s potential is bolstered by its non-classification as a controlled substance by the DEA, facilitating its clinical development. Additionally, MIRA is advancing its acquisition of SKNY Pharmaceuticals, with SKNY-1 showing significant potential in treating obesity and nicotine addiction. The SEC has approved the merger proxy, allowing MIRA to proceed with the acquisition, further strengthening its market position.
The most recent analyst rating on (MIRA) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on MIRA Pharmaceuticals, Inc. stock, see the MIRA Stock Forecast page.
More about MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing non-opioid pain relief solutions. The company is known for its innovative drug candidates like Mira-55, a non-psychoactive marijuana analog, and Ketamir-2, both targeting large and underserved pain markets.
Average Trading Volume: 1,263,792
Technical Sentiment Signal: Hold
For detailed information about MIRA stock, go to TipRanks’ Stock Analysis page.